Literature DB >> 16037132

CHIP (carboxyl terminus of Hsc70-interacting protein) promotes basal and geldanamycin-induced degradation of estrogen receptor-alpha.

Meiyun Fan1, Annie Park, Kenneth P Nephew.   

Abstract

In estrogen target cells, estrogen receptor-alpha (ERalpha) protein levels are strictly regulated. Although receptor turnover is a continuous process, dynamic fluctuations in receptor levels, mediated primarily by the ubiquitin-proteasome pathway, occur in response to changing cellular conditions. In the absence of ligand, ERalpha is sequestered within a stable chaperone protein complex consisting of heat shock protein 90 (Hsp90) and cochaperones. However, the molecular mechanism(s) regulating ERalpha stability and turnover remain undefined. One potential mechanism involves CHIP, the carboxyl terminus of Hsc70-interacting protein, previously shown to target Hsp90-interacting proteins for ubiquitination and proteasomal degradation. In the present study, a role for CHIP in ERalpha protein degradation was investigated. In ER-negative HeLa cells transfected with ERalpha and CHIP, ERalpha proteasomal degradation increased, whereas ERalpha-mediated gene transcription decreased. In contrast, CHIP depletion by small interference RNA resulted in increased ERalpha accumulation and reporter gene transactivation. Transfection of mutant CHIP constructs demonstrated that both the U-box (containing ubiquitin ligase activity) and the tetratricopeptide repeat (TPR, essential for chaperone binding) domains within CHIP are required for CHIP-mediated ERalpha down-regulation. In addition, coimmunoprecipitation assays demonstrated that ERalpha and CHIP associate through the CHIP TPR domain. In ERalpha-positive breast cancer MCF7 cells, CHIP overexpression resulted in decreased levels of endogenous ERalpha protein and attenuation of ERalpha-mediated gene expression. Furthermore, the ERalpha-CHIP interaction was stimulated by the Hsp90 inhibitor geldanamycin (GA), resulting in enhanced ERalpha degradation; this GA effect was further augmented by CHIP overexpression but was abolished by CHIP depletion. Finally, ERalpha dissociation from CHIP by various ERalpha ligands, including 17beta-estradiol, 4-hydroxytamoxifen, and ICI 182,780, interrupted CHIP-mediated ERalpha degradation. These results demonstrate a role for CHIP in both basal and GA-induced ERalpha degradation. Furthermore, based on our observations that CHIP promotes ERalpha degradation and attenuates receptor-mediated gene transcription, we suggest that CHIP, by modulating ERalpha stability, contributes to the regulation of functional receptor levels, and thus hormone responsiveness, in estrogen target cells.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16037132     DOI: 10.1210/me.2005-0111

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  87 in total

1.  Aptamer-Enabled Manipulation of the Hsp70 Chaperone System Suggests a Novel Strategy for Targeted Ubiquitination.

Authors:  Deepak Thirunavukarasu; Hua Shi
Journal:  Nucleic Acid Ther       Date:  2015-12-07       Impact factor: 5.486

2.  Tumor suppressor function of RUNX3 in breast cancer.

Authors:  Lin-Feng Chen
Journal:  J Cell Biochem       Date:  2012-05       Impact factor: 4.429

3.  Turning off estrogen receptor beta-mediated transcription requires estrogen-dependent receptor proteolysis.

Authors:  Yukiyo Tateishi; Raku Sonoo; Yu-ichi Sekiya; Nanae Sunahara; Miwako Kawano; Mitsutoshi Wayama; Ryuichi Hirota; Yoh-ichi Kawabe; Akiko Murayama; Shigeaki Kato; Keiji Kimura; Junn Yanagisawa
Journal:  Mol Cell Biol       Date:  2006-08-28       Impact factor: 4.272

4.  Antiviral activity and RNA polymerase degradation following Hsp90 inhibition in a range of negative strand viruses.

Authors:  John H Connor; Margie O McKenzie; Griffith D Parks; Douglas S Lyles
Journal:  Virology       Date:  2007-01-26       Impact factor: 3.616

5.  Akt shows variable sensitivity to an Hsp90 inhibitor depending on cell context.

Authors:  Maria A Theodoraki; Mary Kunjappu; David W Sternberg; Avrom J Caplan
Journal:  Exp Cell Res       Date:  2007-07-06       Impact factor: 3.905

6.  Estrogen replacement regimen and brain infusion of lipopolysaccharide differentially alter steroid receptor expression in the uterus and hypothalamus.

Authors:  L K Marriott; K R McGann-Gramling; B Hauss-Wegrzyniak; L C Sheldahl; R A Shapiro; D M Dorsa; G L Wenk
Journal:  Endocrine       Date:  2008-02-05       Impact factor: 3.633

7.  Estrogen inhibits transforming growth factor beta signaling by promoting Smad2/3 degradation.

Authors:  Ichiaki Ito; Aki Hanyu; Mitsutoshi Wayama; Natsuka Goto; Yoko Katsuno; Shohei Kawasaki; Yuka Nakajima; Masashi Kajiro; Yoko Komatsu; Akiko Fujimura; Ryuichi Hirota; Akiko Murayama; Keiji Kimura; Takeshi Imamura; Junn Yanagisawa
Journal:  J Biol Chem       Date:  2010-03-05       Impact factor: 5.157

8.  A mechanism emerges for the critical period hypothesis for estrogen treatment.

Authors:  John H Morrison
Journal:  Proc Natl Acad Sci U S A       Date:  2011-08-19       Impact factor: 11.205

9.  Estrogen receptor-alpha hinge-region lysines 302 and 303 regulate receptor degradation by the proteasome.

Authors:  Nicholas B Berry; Meiyun Fan; Kenneth P Nephew
Journal:  Mol Endocrinol       Date:  2008-04-03

10.  Prognostic implications of carboxyl-terminus of Hsc70 interacting protein and lysyl-oxidase expression in human breast cancer.

Authors:  Neill Patani; Wen Jiang; Robert Newbold; Kefah Mokbel
Journal:  J Carcinog       Date:  2010-11-12
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.